Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
El sistema renina-angiotensina-aldosterona y sus inhibidores en el contexto de la pandemia por COVID-19 / The renin-angiotensin-aldosterone system and its inhibitors in the context of the COVID-19 pandemic
Resumen
Resumen
Una de las confusiones que ha generado la pandemia de COVID-19 es la idea de que los inhibidores de la enzima convertidora de la angiotensina y los antagonistas del receptor de la angiotensina II de tipo 1 pueden agravar el daño pulmonar inducido por el SARS-CoV-2 en pacientes de edad avanzada. En este breve comunicado se analiza, desde una perspectiva crítica, la evidencia científica que secunda esta asociación.
Abstract
One of the confusions aroused by the outbreak of COVID-19 pandemic is the idea that angiotensin converting enzyme inhibitors and type 1 angiotensin II receptor may aggravate the lung damage induced by SARS CoV-2 virus in older adult patients. In this brief statement, the scientific evidence supporting this association is analyzed from a critical perspective.
Palabras clave
Referencias
Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI/ARB of patients with Covid-19 complicated by hypertension. Hypert Res. 2020;43(6):588-90.
Mourad Jl, Levy BI. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat Rev Cardiol. 2020;17(5):313.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653-9.
Instituto Nacional de Salud, Secretaría de Salud. Encuesta Nacional de Salud y Nutrición de medio camino. 2016. Disponible en:https://www.gob.mx/cms/uploads/attachment/file/209093/ENSANUT.pdf.
Borghi C, Rossi F. Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases:complex and critical issues. High Blood Pressure Cardiovasc Prev. 2015;22:429-44.
Lavoie JL, Sigmund CD. Minireview:overview of the renin-angiotensin system. Endocrinology. 2003;144:2179-83.
Miller AJ, Arnold AC. The renin-angiotensin system —an endocrine and paracrine system. Clin Auton Res. 2019;29:231-43.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin to angiotensin 1-9. Circ Res. 2000;87:E1-9.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS Coronavirus-induced lung injury. Nat Med. 2005;11:875-9.
Li W, Moore MJ, Vasileva, Sui J, Wong SK, Berne MA, et al. Angiotensin converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-4.
Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, et al. Soluble angiotensin converting enzyme in human heart failure:relation with myocardial function and clinical outcomes. J Card Fail. 2009;15:565-71.
Furihashi M, Moniwa T, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients maybe increased by Olmesartan, an angiotensin II receptor blocker. Am J Hypert. 2015;28:15-21.
DOI: https://doi.org/10.24875/RMIMSS.M20000059
Enlaces refback
- No hay ningún enlace refback.